Literature DB >> 22778259

Ligand-mimicking receptor variant discloses binding and activation mode of prolactin-releasing peptide.

Daniel Rathmann1, Diana Lindner, Stephanie H DeLuca, Kristian W Kaufmann, Jens Meiler, Annette G Beck-Sickinger.   

Abstract

The prolactin-releasing peptide receptor and its bioactive RF-amide peptide (PrRP20) have been investigated to explore the ligand binding mode of peptide G-protein-coupled receptors (GPCRs). By receptor mutagenesis, we identified the conserved aspartate in the upper transmembrane helix 6 (Asp(6.59)) of the receptor as the first position that directly interacts with arginine 19 of the ligand (Arg(19)). Replacement of Asp(6.59) with Arg(19) of PrRP20 led to D6.59R, which turned out to be a constitutively active receptor mutant (CAM). This suggests that the mutated residue at the top of transmembrane helix 6 mimics Arg(19) by interacting with additional binding partners in the receptor. Next, we generated an initial comparative model of this CAM because no ligand docking was required, and we selected the next set of receptor mutants to find the engaged partners of the binding pocket. In an iterative process, we identified two acidic residues and two hydrophobic residues that form the peptide ligand binding pocket. As all residues are localized on top or in the upper part of the transmembrane domains, we clearly can show that the extracellular surface of the receptor is sufficient for full signal transduction for prolactin-releasing peptide, rather than a deep, membrane-embedded binding pocket. This contributes to the knowledge of the binding of peptide ligands to GPCRs and might facilitate the development of GPCR ligands, but it also provides new targeting of CAMs involved in hereditary diseases.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22778259      PMCID: PMC3442549          DOI: 10.1074/jbc.M112.349852

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  68 in total

1.  Severe congenital hyperthyroidism caused by a germ-line neo mutation in the extracellular portion of the thyrotropin receptor.

Authors:  A Grüters; T Schöneberg; H Biebermann; H Krude; H P Krohn; H Dralle; T Gudermann
Journal:  J Clin Endocrinol Metab       Date:  1998-05       Impact factor: 5.958

Review 2.  Defects in G protein-coupled signal transduction in human disease.

Authors:  A M Spiegel
Journal:  Annu Rev Physiol       Date:  1996       Impact factor: 19.318

3.  Structural instability of a constitutively active G protein-coupled receptor. Agonist-independent activation due to conformational flexibility.

Authors:  U Gether; J A Ballesteros; R Seifert; E Sanders-Bush; H Weinstein; B K Kobilka
Journal:  J Biol Chem       Date:  1997-01-31       Impact factor: 5.157

4.  A prolactin-releasing peptide in the brain.

Authors:  S Hinuma; Y Habata; R Fujii; Y Kawamata; M Hosoya; S Fukusumi; C Kitada; Y Masuo; T Asano; H Matsumoto; M Sekiguchi; T Kurokawa; O Nishimura; H Onda; M Fujino
Journal:  Nature       Date:  1998-05-21       Impact factor: 49.962

5.  Sequence and tissue distribution of a candidate G-coupled receptor cloned from rat hypothalamus.

Authors:  S K Welch; B F O'Hara; T S Kilduff; H C Heller
Journal:  Biochem Biophys Res Commun       Date:  1995-04-17       Impact factor: 3.575

6.  Activating and inactivating mutations in N- and C-terminal i3 loop junctions of muscarinic acetylcholine Hm1 receptors.

Authors:  P Högger; M S Shockley; J Lameh; W Sadée
Journal:  J Biol Chem       Date:  1995-03-31       Impact factor: 5.157

7.  CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice.

Authors:  J D Thompson; D G Higgins; T J Gibson
Journal:  Nucleic Acids Res       Date:  1994-11-11       Impact factor: 16.971

8.  Constitutively active mutants of the alpha 1B-adrenergic receptor: role of highly conserved polar amino acids in receptor activation.

Authors:  A Scheer; F Fanelli; T Costa; P G De Benedetti; S Cotecchia
Journal:  EMBO J       Date:  1996-07-15       Impact factor: 11.598

Review 9.  Functional and clinical consequences of mutations in the FSH receptor.

Authors:  J Gromoll; M Simoni; V Nordhoff; H M Behre; C De Geyter; E Nieschlag
Journal:  Mol Cell Endocrinol       Date:  1996-12-20       Impact factor: 4.102

10.  Pharmacology of a constitutively active muscarinic receptor generated by random mutagenesis.

Authors:  T A Spalding; E S Burstein; H Brauner-Osborne; D Hill-Eubanks; M R Brann
Journal:  J Pharmacol Exp Ther       Date:  1995-12       Impact factor: 4.030

View more
  5 in total

Review 1.  Understanding Peptide Binding in Class A G Protein-Coupled Receptors.

Authors:  Irina G Tikhonova; Veronique Gigoux; Daniel Fourmy
Journal:  Mol Pharmacol       Date:  2019-07-10       Impact factor: 4.436

2.  Design of a Long-Acting and Selective MEG-Fatty Acid Stapled Prolactin-Releasing Peptide Analog.

Authors:  Elsa Pflimlin; Sam Lear; Candy Lee; Shan Yu; Huafei Zou; Andrew To; Sean Joseph; Van Nguyen-Tran; Matthew S Tremblay; Weijun Shen
Journal:  ACS Med Chem Lett       Date:  2019-07-05       Impact factor: 4.345

3.  Small-molecule ligand docking into comparative models with Rosetta.

Authors:  Steven A Combs; Samuel L Deluca; Stephanie H Deluca; Gordon H Lemmon; David P Nannemann; Elizabeth D Nguyen; Jordan R Willis; Jonathan H Sheehan; Jens Meiler
Journal:  Nat Protoc       Date:  2013-06-06       Impact factor: 13.491

4.  Pancreatic polypeptide is recognized by two hydrophobic domains of the human Y4 receptor binding pocket.

Authors:  Xavier Pedragosa-Badia; Gregory R Sliwoski; Elizabeth Dong Nguyen; Diana Lindner; Jan Stichel; Kristian W Kaufmann; Jens Meiler; Annette G Beck-Sickinger
Journal:  J Biol Chem       Date:  2013-12-27       Impact factor: 5.157

Review 5.  The Structural Basis of Peptide Binding at Class A G Protein-Coupled Receptors.

Authors:  Oanh Vu; Brian Joseph Bender; Lisa Pankewitz; Daniel Huster; Annette G Beck-Sickinger; Jens Meiler
Journal:  Molecules       Date:  2021-12-30       Impact factor: 4.411

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.